Skip to main content
OpenTrials
Completed

NCT Number: NCT01924143

TD-9855 Mass Balance Study

The purpose of the study is to evaluate the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of [14C]TD-9855

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Lincoln, Nebraska, 68502, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy, nonsmoking male subjects or healthy, nonsmoking female subjects not of childbearing potential, 18 to 50 years old, inclusive. Women are considered to be not of childbearing potential if they have had a hysterectomy or tubal ligation or are at least 2 years postmenopausal (follicle-stimulating hormone [FSH] >40 IU/mL)
  • Body mass index 19 to 31 kg/m2, inclusive, and weight at least 55 kg
  • Negative for hepatitis B, hepatitis C, and HIV antibody

Exclusion criteria

  • Have evidence or history of clinically significant allergic (except for untreated, asymptomatic, seasonal allergies at time of dosing), hematological, endocrine, dermatologic, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease
  • Subjects who, in the opinion of the investigator, are at risk for suicide or risk of harming others, or who score positive on the C-SSRS (item 2 or higher on ideation). Subjects with any history of suicide attempts
  • Any condition possibly affecting drug absorption (e.g., previous surgery on the gastrointestinal tract [including removal of parts of the stomach, bowel, liver, gall bladder, or pancreas])
  • Infrequent bowel movements (less than once per 24 hours) in the last 7 days prior to Day -1. Subject is unable to provide a fecal sample prior to study drug dosing on Day -1 or Day 1.

Treatment and study plan

TD-9855

Drug

radiolabeled (100 µCi [14C]-Labeled) TD-9855 (20 mg)

Primary outcomes

  1. To define the routes and rates of elimination and mass balance of [14C]-labeled TD-9855

    Time frame: 1-21 Days

    Urinary and fecal recovery of total radioactivity. Whole blood and plasma concentrations of total radioactivity.

Secondary outcomes

  1. Pharmacokinetics of total drug-related material and TD-9855: Cmax

    Time frame: 1-21 Days

    Whole blood and plasma concentrations

  2. PK: Tmax

    Time frame: 1-21 Days

    Whole blood and plasma concentrations

  3. PK: AUCt

    Time frame: 1-21 Days

    Whole blood and plasma concentrations

  4. PK: AUCinf

    Time frame: 1-21 Days

  5. PK: CL/F (Renal clearance)

    Time frame: 1-21 Days

    Urine

  6. PK: Vz/F (oral volume of distribution during the terminal phase)

    Time frame: 1-21 Days

  7. PK: amount excreted in urine (Ae)

    Time frame: 1-21 Days

    Urine

  8. PK: CLR (Renal clearance, computed as amount recovered in urine/ AUCinf)

    Time frame: 8-21 Days

    Urine

  9. Metabolic profiles in plasma and excreta

    Time frame: 1-21 days

Sponsors and collaborators

Lead sponsor

Theravance Biopharma

Industry

Registry information

Official study title

An Open-Label Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of TD-9855 Following a Single Oral Dose Containing Approximately 100 µCi [14C]-Labeled TD-9855 (20 mg) in Healthy Subjects

Important dates

Study start
2013
Primary completion
2013
Study completion
2013
First posted
Aug 16, 2013
Registry last updated
Jan 19, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.